Each week, we like to take a moment to boil down the biggest news from the most influential companies in the pharmaceuticals industry, and tell our viewers what that news means for you. We call that segment our Big Pharma Roundup.

In this week's installment, Motley Fool health care analyst Brenton Flynn discusses talk from a recent Reuters article, suggesting that hearing loss may actually be the next big target for big pharma. As it becomes harder and harder to find diseases affecting large patient populations that companies can develop game-changing drugs for, some see the hearing loss space as a huge potential market. It has normally been targeted only by medical devices such as hearing aids, but several big pharma companies are now working to develop treatments, and Pfizer (NYSE:PFE) even has a drug in clinical trials.

Brenton Flynn, Max Macaluso, and The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.